Header Logo

Connection

RACHELLE DOODY to Cholinesterase Inhibitors

Back to Details
This is a "connection" page, showing publications RACHELLE DOODY has written about Cholinesterase Inhibitors.
RACHELLE DOODY
Connection Strength
4.450
Cholinesterase Inhibitors
  1. Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial. J Alzheimers Dis. 2017; 56(4):1495-1504.
    View in: PubMed
    Score: 0.511
  2. Reviewing the role of donepezil in the treatment of Alzheimer's disease. Curr Alzheimer Res. 2012 Sep; 9(7):773-81.
    View in: PubMed
    Score: 0.378
  3. Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies. Neurodegener Dis. 2012; 10(1-4):170-4.
    View in: PubMed
    Score: 0.364
  4. Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. Am J Alzheimers Dis Other Demen. 2010 Mar; 25(2):155-9.
    View in: PubMed
    Score: 0.313
  5. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009 May 05; 72(18):1555-61.
    View in: PubMed
    Score: 0.295
  6. Cholinesterase inhibitors and memantine: best practices. CNS Spectr. 2008 Oct; 13(10 Suppl 16):34-5.
    View in: PubMed
    Score: 0.288
  7. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. Drugs Aging. 2008; 25(2):163-74.
    View in: PubMed
    Score: 0.274
  8. Refining treatment guidelines in Alzheimer's disease. Geriatrics. 2005 Jun; Suppl:14-20.
    View in: PubMed
    Score: 0.229
  9. Current treatments for Alzheimer's disease: cholinesterase inhibitors. J Clin Psychiatry. 2003; 64 Suppl 9:11-7.
    View in: PubMed
    Score: 0.194
  10. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001 Jul-Aug; 12(4):295-300.
    View in: PubMed
    Score: 0.174
  11. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001 Mar; 58(3):427-33.
    View in: PubMed
    Score: 0.170
  12. Therapeutic standards in Alzheimer disease. Alzheimer Dis Assoc Disord. 1999 Nov; 13 Suppl 2:S20-6.
    View in: PubMed
    Score: 0.155
  13. Clinical benefits of a new piperidine-class AChE inhibitor. Eur Neuropsychopharmacol. 1999 Apr; 9 Suppl 2:S69-77.
    View in: PubMed
    Score: 0.149
  14. Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology. 1999; 45 Suppl 1:23-32.
    View in: PubMed
    Score: 0.147
  15. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatr. 2013 Jun 06; 13:56.
    View in: PubMed
    Score: 0.100
  16. Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimers Dement. 2013 May; 9(3):338-45.
    View in: PubMed
    Score: 0.096
  17. Donepezil treatment of patients with MCI: a 48-week randomized, placebo- controlled trial. Neurology. 2009 Nov 03; 73(18):1514-5; author reply 1515-6.
    View in: PubMed
    Score: 0.078
  18. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):260-7.
    View in: PubMed
    Score: 0.076
  19. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement. 2008 Mar; 4(2):145-53.
    View in: PubMed
    Score: 0.069
  20. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging. 2006 Sep-Oct; 10(5):417-29.
    View in: PubMed
    Score: 0.062
  21. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord. 2005; 20(6):338-44.
    View in: PubMed
    Score: 0.058
  22. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005 Jun 09; 352(23):2379-88.
    View in: PubMed
    Score: 0.057
  23. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003 Aug 26; 61(4):479-86.
    View in: PubMed
    Score: 0.051
  24. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001 Aug 14; 57(3):481-8.
    View in: PubMed
    Score: 0.044
  25. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998 May 11; 158(9):1021-31.
    View in: PubMed
    Score: 0.035
  26. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 Jan; 50(1):136-45.
    View in: PubMed
    Score: 0.034
  27. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007 Jul 31; 69(5):459-69.
    View in: PubMed
    Score: 0.017
  28. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008 Sep; 29(9):1285-95.
    View in: PubMed
    Score: 0.016
  29. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother. 2006; 4 Suppl A:S9-S24; quiz S25-S28.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.